Artivion, Inc. (NYSE:AORT) Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund trimmed its holdings in Artivion, Inc. (NYSE:AORT) by 10.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,334 shares of the company’s stock after selling 2,718 shares during the period. Illinois Municipal Retirement Fund’s holdings in Artivion were worth $417,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its stake in Artivion by 37.3% in the 3rd quarter. First Eagle Investment Management LLC now owns 526,528 shares of the company’s stock valued at $7,982,000 after acquiring an additional 143,146 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Artivion by 0.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 317,995 shares of the company’s stock valued at $4,821,000 after acquiring an additional 2,659 shares during the last quarter. GSA Capital Partners LLP grew its stake in Artivion by 187.5% in the 3rd quarter. GSA Capital Partners LLP now owns 82,449 shares of the company’s stock valued at $1,250,000 after acquiring an additional 53,773 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in Artivion in the 3rd quarter valued at about $1,034,000. Finally, Exchange Traded Concepts LLC purchased a new position in Artivion in the 4th quarter valued at about $916,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on AORT shares. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Artivion in a report on Monday, April 8th. Stifel Nicolaus upped their target price on shares of Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 16th.

Insider Transactions at Artivion

In related news, CEO James P. Mackin sold 72,069 shares of Artivion stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $18.85, for a total transaction of $1,358,500.65. Following the transaction, the chief executive officer now owns 539,036 shares in the company, valued at approximately $10,160,828.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO James P. Mackin sold 72,069 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $18.85, for a total value of $1,358,500.65. Following the completion of the sale, the chief executive officer now owns 539,036 shares in the company, valued at $10,160,828.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Amy Horton sold 1,695 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $18.86, for a total value of $31,967.70. Following the transaction, the chief accounting officer now directly owns 122,345 shares in the company, valued at $2,307,426.70. The disclosure for this sale can be found here. Insiders sold 149,952 shares of company stock valued at $2,891,627 over the last 90 days. Corporate insiders own 8.10% of the company’s stock.

Artivion Trading Up 3.6 %

Shares of AORT stock opened at $20.33 on Thursday. The firm has a market cap of $837.60 million, a P/E ratio of -27.11 and a beta of 1.67. Artivion, Inc. has a 1-year low of $12.16 and a 1-year high of $21.90. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43. The firm’s 50-day simple moving average is $20.35 and its 200-day simple moving average is $17.87.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.24. The business had revenue of $93.67 million for the quarter, compared to analyst estimates of $89.75 million. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. As a group, equities analysts forecast that Artivion, Inc. will post 0.26 EPS for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.